Vivek Subbiah/X
May 4, 2025, 13:37
Vivek Subbiah highlights Deepak Bhamidipati’s poster on Project Optimus and early-phase trial design at AACR25
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a post on X:
“Fantastic poster AACR25 by our newest Phase 1 clinical trial oncologist, Dr. Deepak Bhamidipati!
His first presentation post-fellowship highlights. The impact of Project Optimus and FDA guidance on early-phase trial design.
Join us in welcoming him to the drug development world.”
Learn more about drug development on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 4, 2025, 13:27
May 4, 2025, 13:12
May 4, 2025, 12:59
May 4, 2025, 12:58
May 4, 2025, 12:45
May 4, 2025, 12:33